Shots: The P-I/II dose expansion studies evaluate the safety & preliminary anti-tumor efficacy of VT1021 as monothx. in patients with dose-escalation & expansion cohorts with rGBM & PC. The results […]readmore
Tags : Pancreatic cancer
In a recent interview with PharmaShots, Dr. Jing Watnick, Co-Founder and Chief Executive Officer, and Dr. Lou Vaickus, Interim Chief Medical Officer at Vigeo shared their views on the data […]readmore
Shots: EMA’s COMP has granted a positive opinion for an ODD status to its PBP1510 for the treatment of pancreatic cancer. COMP’s positive will be sent to the EC which […]readmore
Shots: The EC has granted ODD to Motixafortide (BL-8040) for the treatment of pancreatic cancer following the positive COMP’s opinion The ODD designation is based on initial data of ongoing […]readmore
Shots: InxMed to sponsor the trial while Merck & Co (MSD outside the United States and Canada) will provide pembrolizumab for evaluation in the trial The focus of the […]readmore
Shots: OBI Pharma has initiated the enrollment of P-I/II study at the University of Texas M.D. Anderson Cancer Center to evaluate the therapy in patients with LA/m-solid tumors The objective […]readmore
Shots: The US FDA’s Center for Devices and Radiological Health has granted breakthrough device designation for Shreis’ Cytotron, invented by Dr. Rajah Vijay Kumar in Bengaluru, India, indicated for the […]readmore
Shots: The FDA’s ODD to BL-8040 is granted for pancreatic cancer, with an addition to previously granted for AML and stem-cell mobilization in 2015 The US FDA’s ODD is granted […]readmore
Shots: The Fourth ODD is based on the ongoing P-III POLO study assessing Lynparza (300mg bid) as monotherapy vs PBO in ratio (3:2) & 1EP as PFS in 145 patients […]readmore
Shots: Under the expansion collaboration, new arm of assessment is added assessing BL-8040, Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study Results of Ph2a COMBAT study is expected in […]readmore